Deal Tracker · Countries

Oman pharma deals

20 pharma deals involving Oman — companies based there or deals covering the market — tracked by EPT: distribution, investment & partnerships. Most active: Khazaen Economic City, Taiba Healthcare, Dhofar Pharmaceutical Industries & JCR Pharmaceuticals. Latest: Emmaus Life Sciences → Al Wataniya Aldawliya (Distribution, 12 Nov 2026).

20
deals tracked
16
announced in 2026
$234m
disclosed value (6 deals)
25%
distribution, the top deal type
  • EPT has tracked 20 Oman pharma deals (2022–2026), 16 of them announced in 2026.
  • The most common structures are distribution (25%), investment (25%) & partnerships (20%).
  • Values were disclosed for 6 of 20 deals, totalling $234m; the largest is Daewoong Pharmaceutical → Arcera Life Sciences ($94m, 29 Jun 2026).
  • The most active companies: Khazaen Economic City (3), Taiba Healthcare (3), Dhofar Pharmaceutical Industries (2) & JCR Pharmaceuticals (2).

Countries involved

Saudi Arabia (8) · UAE (8) · Bahrain (7) · Kuwait (7) · Qatar (5) · Algeria (3)

Largest disclosed deals

Questions

How many Oman pharma deals has EPT tracked?
20 as of 12 Nov 2026, covering 2022–2026; 16 were announced in 2026. The most recent is Emmaus Life Sciences → Al Wataniya Aldawliya (Distribution, 12 Nov 2026).
What types of Oman pharma deals are most common?
Distribution: 5 (25%); Equity / Investment: 5 (25%); Partnership / Collaboration: 4 (20%); Technology transfer / Localization: 2 (10%).
Which companies are most active in Oman pharma deals?
Khazaen Economic City (3 deals), Taiba Healthcare (3 deals), Dhofar Pharmaceutical Industries (2 deals), JCR Pharmaceuticals (2 deals), Philex Pharmaceuticals (2 deals).
What is the largest disclosed Oman pharma deal?
Daewoong Pharmaceutical → Arcera Life Sciences: $94m (Licensing, 29 Jun 2026); Al Badr Trading & Industry, Lamaa Pharma, Al Mansoor + 1 other → Khazaen Economic City: $52m (Equity / Investment, 1 Nov 2026); Gulf Pharmaceutical Industries and Medical Devices → Khazaen Economic City: $39m (Equity / Investment, 14 Jan 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)